BACKGROUND: Palliative sedation therapy (PST) is indicated for and used to control refractory symptoms in cancer patients undergoing palliative care. We aimed to evaluate whether PST has a detrimental effect on survival in terminally ill patients. METHODS: This multicenter, observational, prospective, nonrandomized population-based study evaluated overall survival in two cohorts of hospice patients, one submitted to palliative sedation (A) and the other managed as per routine hospice practice (B). Cohorts were matched for age class, gender, reason for hospice admission, and Karnofsky performance status. RESULTS: Of the 518 patients enrolled, 267 formed cohort A and 251 cohort B. In total, 25.1% of patients admitted to the participating hospices received PST. Mean and median duration of sedation was 4 (standard deviation 6.0) and 2 days (range 0-43), respectively. Median survival of arm A was 12 days [90% confidence interval (CI) 10-14], while that of arm B was 9 days (90% CI 8-10) (log rank = 0.95, P = 0.330) (unadjusted hazard ratio = 0.92, 90% CI 0.80-1.06). CONCLUSION: PST does not shorten life when used to relieve refractory symptoms and does not need the doctrine of double effect to justify its use from an ethical point of view.
BACKGROUND: Palliative sedation therapy (PST) is indicated for and used to control refractory symptoms in cancerpatients undergoing palliative care. We aimed to evaluate whether PST has a detrimental effect on survival in terminally ill patients. METHODS: This multicenter, observational, prospective, nonrandomized population-based study evaluated overall survival in two cohorts of hospice patients, one submitted to palliative sedation (A) and the other managed as per routine hospice practice (B). Cohorts were matched for age class, gender, reason for hospice admission, and Karnofsky performance status. RESULTS: Of the 518 patients enrolled, 267 formed cohort A and 251 cohort B. In total, 25.1% of patients admitted to the participating hospices received PST. Mean and median duration of sedation was 4 (standard deviation 6.0) and 2 days (range 0-43), respectively. Median survival of arm A was 12 days [90% confidence interval (CI) 10-14], while that of arm B was 9 days (90% CI 8-10) (log rank = 0.95, P = 0.330) (unadjusted hazard ratio = 0.92, 90% CI 0.80-1.06). CONCLUSION: PST does not shorten life when used to relieve refractory symptoms and does not need the doctrine of double effect to justify its use from an ethical point of view.
Authors: Ian Koper; Agnes van der Heide; Rien Janssens; Siebe Swart; Roberto Perez; Judith Rietjens Journal: Support Care Cancer Date: 2013-09-14 Impact factor: 3.603
Authors: Sebastiano Mercadante; Francesco Masedu; Alessandro Mercadante; Franco Marinangeli; Federica Aielli Journal: Support Care Cancer Date: 2017-01-17 Impact factor: 3.603
Authors: Ferraz Gonçalves; Aida Cordero; Ana Almeida; Arlindo Cruz; Céu Rocha; Madalena Feio; Paula Silva; Salomé Barbas; Sandra Neves Journal: Support Care Cancer Date: 2012-03-24 Impact factor: 3.603
Authors: Marco Maltoni; Guido Miccinesi; Piero Morino; Emanuela Scarpi; Francesco Bulli; Francesca Martini; Filippo Canzani; Monia Dall'Agata; Eugenio Paci; Dino Amadori Journal: Support Care Cancer Date: 2012-02-24 Impact factor: 3.603
Authors: Doralina L Anghelescu; Hunter Hamilton; Lane G Faughnan; Liza-Marie Johnson; Justin N Baker Journal: J Palliat Med Date: 2012-06-25 Impact factor: 2.947
Authors: Augusto Caraceni; Ernesto Zecca; Cinzia Martini; Giovanna Gorni; Tiziana Campa; Cinzia Brunelli; Franco De Conno Journal: Support Care Cancer Date: 2011-07-16 Impact factor: 3.603